Navigation Links
Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
Date:9/9/2008

and uncertainties not discussed herein may be found in the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2007.

About Alpharma

Alpharma Inc. (NYSE: ALO) is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 80 countries. Alpharma has a growing branded pharmaceutical franchise in the U.S. pain market with its KADIAN(R) (morphine sulfate extended-release) Capsules, and the FLECTOR(R) Patch (diclofenac epolamine topical patch). In addition, Alpharma is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.

Alpharma press releases are also available at our website, http://www.alpharma.com.

Contact: Jack Howarth

Vice President, Investor Relations

908-566-4153

Jack.howarth@alpharma.com

References

1. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA. 2007; 297:249-251.

2. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007; 23:648-660.

3. Woolf CJ, Hashmi M. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Invest Drugs. 2004; 5:61-66.

4. Gagnon AM, Kahan M, Srivastava A. Opioid use and abuse: is there a problem? Clin J Pain. 2007; 23:661-662.

5. Birnbaum HG, Whiate AG, Reynolds JL, et al. Estimated costs of prescriptio
'/>"/>

SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Ill. , March 4, 2015 The March 3, ... of testosterone drugs must change their products, labels to clarify ... of heart attack and stroke is necessary to protect the ... Miracle , a partner at Simmons Hanly Conroy . ... indicate on labels that the products – currently taken by ...
(Date:3/4/2015)... KANSAS CITY, Kan. , March 4, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the licensing, ... animals, today announced that it will present at the ... March 10-12, 2015, at the Loews Miami Beach Hotel ... Steven St. Peter , M.D., President and ...
(Date:3/4/2015)...  Bayer HealthCare today announced that the U.S. ... company,s Biologics License Application (BLA) for BAY 81-8973, ... FDA approval of the investigational compound, proposed trade ... in children and adults. "Bayer ... hemophilia A patients who need them," said ...
Breaking Medicine Technology:Simmons Hanly Conroy, LLC: FDA Orders Label Warnings on Testosterone Drugs Concerning Normal Aging Use and Heart Attack-Stroke Risks 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3
... , May 24 Watson Pharmaceuticals, Inc. (NYSE: ... has received approval from the United States Food and Drug Administration ... USP, in the 500 and 1000 mg strengths, the generic equivalent ... product shortly.   , , ...
... May 24 ExpertRECALL, the leader in the field of recall ... study of recall logistics management in the food, drug and consumer products ... Mary Swartz with Michaels Stores, Inc. , ... Upon completion of their studies at Saint Louis ...
Cached Medicine Technology:Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 2Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 3ExpertRECALL Awards First Scholarships for Product-Safety Education 2
(Date:3/4/2015)... March 04, 2015 Cook For Your ... that teaches healthy cooking to people touched by cancer, ... Lodge. The program, run by founder Ann Ogden, will ... Sport Management. The unique partnership will expand the program ... founded CFYL in 2007. After going through her own ...
(Date:3/4/2015)... 2015 Blake’s All Natural Foods ... will attend this year’s Natural Products Expo West in ... With this new line, Blake’s, who has the top ... continues its commitment to creating high-quality dishes that are ... in the natural channel, Blake’s understands what educated consumers ...
(Date:3/4/2015)... Alliance Healthcare Foundation (AHF), a non-profit organization working ... in San Diego and Imperial Counties, announced today that ... Grants program with awards totaling $1 million. , ... Support Grants program. Grant recipients were chosen through a ... committee, as well as the community as a whole. ...
(Date:3/4/2015)... 2015 As seen on Advanced ... can be a painful condition in which the lining ... the uterus leading to very unpleasant symptoms and complications ... have a terrible effect on women’s quality of life ... most common cause of infertility in women and carries ...
(Date:3/4/2015)... Farge, Wis. (PRWEB) March 04, 2015 Organic ... leading organic brand, today announced its cause campaign to Save ... gone viral and is making a difference to Bros everywhere. ... views on Youtube and Facebook. The video was named ... was featured in Forbes, Mashable and Digiday, among other media ...
Breaking Medicine News(10 mins):Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 2Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 3Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 3Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3
... association between sleep problems and increased risk of fibromyalgia ... of sleep problems, and the association was stronger among ... of the prospective study, based on ten years of ... journal published by Wiley-Blackwell on behalf of the American ...
... FRANCISCO Patients with non-small cell lung cancer who have ... antifolate class of drugs, according to results of a recent ... and patients. "Our findings indicate that when patients ... they become very amenable to antifolate drugs," said lead researcher ...
... , SUNDAY, Nov. 13 (HealthDay News) -- Fibromyalgia patients ... six weeks reported improved memory function and less pain, ... finding is encouraging, it does not suggest a potential ... authors stressed. Senior author Dr. Brian Walitt, director ...
... Mann HealthDay Reporter , SUNDAY, Nov. 13 (HealthDay ... drug called Xarelto (rivaroxaban) may help people with "acute coronary ... stroke, a new study finds. Acute coronary syndrome is ... history of heart attack. The finding "opens up a ...
... California, San Diego School of Medicine and the UC ... drug discovery approach enabling the destruction of the most ... 13 online issue of the journal Nature Medicine ... fast-growing cancer cells without causing some of the negative ...
... scaling was associated with fewer heart attacks and strokes in ... Heart Association,s Scientific Sessions 2011. , Among more than 100,000 ... scaling) by a dentist or dental hygienist had a 24 ... risk of stroke compared to those who had never had ...
Cached Medicine News:Health News:Poor sleep habits linked to increased risk of fibromyalgia in women 2Health News:Antifolates show promise against NSCLC subtype 2Health News:Study Suggests Exercise May Help Memory of Fibromyalgia Patients 2Health News:Study Suggests Exercise May Help Memory of Fibromyalgia Patients 3Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 2Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 3Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 4Health News:New way to target - and kill - proliferating tumors 2Health News:Professional dental cleanings may reduce risk of heart attack, stroke 2
... protein is a 185 kD trans-membrane glycoprotein ... cases of breast cancer show an amplification ... Since the introduction of Herceptin® as a ... testing of Her-2/neu in breast carcinoma has ...
... of 3 can choose either the PARI LC ... principle applies to both:, ,Maximize aerosol output ... when the patient exhales using two one-way valves. ... the nebulizer. The result is a high percentage ...
... practitioners consider the HOPE nebulizer the gold standard ... made to put everything together in one convenient ... is our #11330 Pediatric HOPE Kit which contains ... and pediatric aerosol mask all in one set ...
... of medication as well as humidification, try ... dilution, high volume, continuous medication nebulizer (CMN), ... patients. Its 200 ml reservoir and jet ... hours of nebulized medication delivery at 25 ...
Medicine Products: